Company
Headquarters: Chongqing, China
Employees: 3,380
CN¥67.43 Billion
CNY as of Jan. 1, 2025
US$9.24 Billion
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Chongqing Zhifei Biological Products Co., Ltd. engages in the research, development, manufacture, and marketing of vaccines and biological products in China. The company was founded in 2009 and is based in Chongqing, China.
| Last Financial Reports Date | Sept. 30, 2024 |
| Revenue TTM | CN¥36.43 B |
| EBITDA | CN¥4.92 B |
| Gross Profit TTM | CN¥14.24 B |
| Profit Margin | 10.13% |
| Operating Margin | -0.88% |
| Quarterly Revenue Growth | -69.50% |
Chongqing Zhifei Biological Products Co. Ltd has the following listings and related stock indices.
Stock: SZSE: 300122 wb_incandescent